These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Watanabe K; Tachibana O; Sata K; Yonekawa Y; Kleihues P; Ohgaki H Brain Pathol; 1996 Jul; 6(3):217-23; discussion 23-4. PubMed ID: 8864278 [TBL] [Abstract][Full Text] [Related]
3. Primary glioblastomas with and without EGFR amplification: relationship to genetic alterations and clinicopathological features. Benito R; Gil-Benso R; Quilis V; Perez M; Gregori-Romero M; Roldan P; Gonzalez-Darder J; Cerdá-Nicolas M; Lopez-Gines C Neuropathology; 2010 Aug; 30(4):392-400. PubMed ID: 20051017 [TBL] [Abstract][Full Text] [Related]
4. Necrogenesis and Fas/APO-1 (CD95) expression in primary (de novo) and secondary glioblastomas. Tohma Y; Gratas C; Van Meir EG; Desbaillets I; Tenan M; Tachibana O; Kleihues P; Ohgaki H J Neuropathol Exp Neurol; 1998 Mar; 57(3):239-45. PubMed ID: 9600216 [TBL] [Abstract][Full Text] [Related]
5. PTEN (MMAC1) mutations are frequent in primary glioblastomas (de novo) but not in secondary glioblastomas. Tohma Y; Gratas C; Biernat W; Peraud A; Fukuda M; Yonekawa Y; Kleihues P; Ohgaki H J Neuropathol Exp Neurol; 1998 Jul; 57(7):684-9. PubMed ID: 9690672 [TBL] [Abstract][Full Text] [Related]
6. PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. Smith JS; Tachibana I; Passe SM; Huntley BK; Borell TJ; Iturria N; O'Fallon JR; Schaefer PL; Scheithauer BW; James CD; Buckner JC; Jenkins RB J Natl Cancer Inst; 2001 Aug; 93(16):1246-56. PubMed ID: 11504770 [TBL] [Abstract][Full Text] [Related]
7. Pathways leading to glioblastoma multiforme: a molecular analysis of genetic alterations in 65 astrocytic tumors. Lang FF; Miller DC; Koslow M; Newcomb EW J Neurosurg; 1994 Sep; 81(3):427-36. PubMed ID: 8057151 [TBL] [Abstract][Full Text] [Related]
9. Roles of the functional loss of p53 and other genes in astrocytoma tumorigenesis and progression. Nozaki M; Tada M; Kobayashi H; Zhang CL; Sawamura Y; Abe H; Ishii N; Van Meir EG Neuro Oncol; 1999 Apr; 1(2):124-37. PubMed ID: 11550308 [TBL] [Abstract][Full Text] [Related]
10. p53 mutation and epidermal growth factor receptor overexpression in glioblastoma. Yoon KS; Lee MC; Kang SS; Kim JH; Jung S; Kim YJ; Lee JH; Ahn KY; Lee JS; Cheon JY J Korean Med Sci; 2001 Aug; 16(4):481-8. PubMed ID: 11511795 [TBL] [Abstract][Full Text] [Related]
11. Alterations of cell cycle regulatory genes in primary (de novo) and secondary glioblastomas. Biernat W; Tohma Y; Yonekawa Y; Kleihues P; Ohgaki H Acta Neuropathol; 1997 Oct; 94(4):303-9. PubMed ID: 9341929 [TBL] [Abstract][Full Text] [Related]
12. Monosomy of chromosome 10 associated with dysregulation of epidermal growth factor signaling in glioblastomas. Yadav AK; Renfrow JJ; Scholtens DM; Xie H; Duran GE; Bredel C; Vogel H; Chandler JP; Chakravarti A; Robe PA; Das S; Scheck AC; Kessler JA; Soares MB; Sikic BI; Harsh GR; Bredel M JAMA; 2009 Jul; 302(3):276-89. PubMed ID: 19602687 [TBL] [Abstract][Full Text] [Related]
13. [Study on the expression of epidermal growth factor receptor and p53 in astrocytic gliomas: evidence for a distinct genetic pathway]. Dong L; Pu PY; Wang H; Wang GX; Kang CS; Jiao DR Zhonghua Bing Li Xue Za Zhi; 2006 Apr; 35(4):232-6. PubMed ID: 16776982 [TBL] [Abstract][Full Text] [Related]
14. Molecular analysis of microdissected de novo glioblastomas and paired astrocytic tumors. Cheng Y; Ng HK; Ding M; Zhang SF; Pang JC; Lo KW J Neuropathol Exp Neurol; 1999 Feb; 58(2):120-8. PubMed ID: 10029095 [TBL] [Abstract][Full Text] [Related]
15. Amplification of genes encoding KIT, PDGFRalpha and VEGFR2 receptor tyrosine kinases is frequent in glioblastoma multiforme. Joensuu H; Puputti M; Sihto H; Tynninen O; Nupponen NN J Pathol; 2005 Oct; 207(2):224-31. PubMed ID: 16021678 [TBL] [Abstract][Full Text] [Related]
16. Analysis of p53 mutation and epidermal growth factor receptor amplification in recurrent gliomas with malignant progression. Reifenberger J; Ring GU; Gies U; Cobbers L; Oberstrass J; An HX; Niederacher D; Wechsler W; Reifenberger G J Neuropathol Exp Neurol; 1996 Jul; 55(7):822-31. PubMed ID: 8965097 [TBL] [Abstract][Full Text] [Related]
17. Genetic sub-types of human malignant astrocytoma correlate with survival. Leenstra S; Oskam NT; Bijleveld EH; Bosch DA; Troost D; Hulsebos TJ Int J Cancer; 1998 Apr; 79(2):159-65. PubMed ID: 9583731 [TBL] [Abstract][Full Text] [Related]
18. Acquisition of the glioblastoma phenotype during astrocytoma progression is associated with loss of heterozygosity on 10q25-qter. Fujisawa H; Kurrer M; Reis RM; Yonekawa Y; Kleihues P; Ohgaki H Am J Pathol; 1999 Aug; 155(2):387-94. PubMed ID: 10433932 [TBL] [Abstract][Full Text] [Related]
19. Genetic Alterations of Epidermal Growth Factor Receptor in Glioblastoma: The Usefulness of Immunohistochemistry. Lee M; Kang SY; Suh YL Appl Immunohistochem Mol Morphol; 2019 Sep; 27(8):589-598. PubMed ID: 29912767 [TBL] [Abstract][Full Text] [Related]
20. p53 protein and epidermal growth factor receptor expression in human astrocytomas. Kordek R; Biernat W; Alwasiak J; Maculewicz R; Yanagihara R; Liberski PP J Neurooncol; 1995 Oct; 26(1):11-6. PubMed ID: 8583240 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]